Participant Flow



Baseline Characteristics

Parameter		Statistic	Overall (N=20)
Age (yrs)		Mean	36.1
		SD	7.49
Height (m)		Mean	1.773
		SD	0.0797
Weight (kg)		Mean	80.88
		SD	14.357
BMI (kg/m^2)		Mean	25.6
		SD	3.7
Race:	White	n (%)	20 (100.0)
Ethnicity:	Non-Hispanic/Latino	n (%)	20 (100.0)
Gender:	Male	n (%)	15 (75.0)
	Female	n (%)	5 (25.0)

Outcome Measures

Table 1: Summary of Baseline Corrected Derived Plasma Nicotine PK Parameters (PK Set)

Product	Summary Statistic	$C_{max,single}$ (ng/ml)	$T_{max,single}$ (min)	AUC_{0-240} (min*ng/ml)	$C_{max,multiple}$ (ng/ml)
Product A	n	19	19	19	20
	Mean	9.17	8.82	500	8.73
	Geo. Mean	7.13	N/A	408	6.69
	SD	7.34	6.09	335	5.84
	SE	1.68	1.40	76.9	1.31
	CV%	80.1	69.1	67.0	66.9
	Min	1.32	5.00	142	1.22
	Median	6.99	7.50	404	7.51
	Max	29.0	30.0	1290	20.6
Product B	n	20	20	20	20
	Mean	13.2	6.13	593	12.5
	Geo. Mean	10.9	N/A	484	10.6
	SD	8.49	1.72	358	8.00
	SE	1.90	0.384	80.1	1.79
	CV%	64.1	28.0	60.4	63.8
	Min	2.97	5.00	111	3.66
	Median	10.9	5.00	487	8.38
	Max	37.5	10.0	1370	34.1

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).
LLOQ = 0.498 ng/ml. For the purposes of PK parameter calculation, BLQ values were set to zero.

Baseline defined as pre-IP use. Any negative values occurring as a result of baseline-correction were set to 0 prior to PK parameter derivation.

Table 2: Summary of Statistical Analysis of Baseline Corrected Derived Plasma Nicotine $C_{max,single}$, $C_{max,multiple}$ and AUC_{0-240} (PK Set)

Parameter	Number in Comparison	Geometric LSMeans (95% CI)		Geometric LSMean Ratio (%) (95% CI)	p-Value for Comparison	Within-Subject CV%
		Product A (N=20)	Product B (N=20)	Product B / Product A		
$C_{max,single}$ (ng/mL)	19	7.11 (5.05 – 10.03)	10.85 (7.69 – 15.29)	152.48 (119.91 – 193.89)	0.0018	36.2

Parameter	Number in Comparison	Geometric LSMeans (95% CI)		Geometric LSMean Ratio (%) (95% CI)	p-Value for Comparison	Within-Subject CV%
		Product A (N=20)	Product B (N=20)	Product B / Product A		
$C_{max,multiple}$ (ng/mL)	20	6.69 (4.84 – 9.26)	10.59 (7.65 – 14.66)	158.24 (116.23 – 215.45)	0.0059	49.1
AUC_{0-240} (min*ng/mL)	19	409.90 (291.84 – 575.73)	492.24 (350.46 – 691.38)	120.09 (92.54 – 155.84)	0.1566	39.4

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).
Results obtained using an ANOVA with fixed effects for sequence, study day and product and a random effect of subject nested within sequence.

Baseline defined as pre-IP use. Any negative values occurring as a result of baseline-correction were set to 0 prior to PK parameter derivation.

Table 3: Summary of Uncorrected Derived Plasma Nicotine PK Parameters (PK Set)

Product	Summary Statistic	$C_{max,single}$ (ng/ml)	$T_{max,single}$ (min)	AUC_{0-240} (min*ng/ml)	$C_{max,multiple}$ (ng/ml)
Product A	n	19	19	19	20
	Mean	10.1	8.82	734	9.68
	Geo. Mean	8.36	N/A	636	7.69
	SD	7.54	6.09	430	6.22
	SE	1.73	1.40	98.5	1.39
	CV%	74.5	69.1	58.5	64.2
	Min	2.30	5.00	192	1.44
	Median	7.91	7.50	645	8.03
	Max	31.0	30.0	2080	24.2
Product B	n	20	20	20	20
	Mean	14.3	6.13	839	13.6
	Geo. Mean	12.3	N/A	763	11.7
	SD	8.38	1.72	398	8.24
	SE	1.87	0.384	88.9	1.84
	CV%	58.7	28.0	47.4	60.8
	Min	5.40	5.00	401	5.33
	Median	12.0	5.00	694	9.78
	Max	38.1	10.0	1870	34.7

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).
LLOQ = 0.498 ng/ml. For the purposes of PK parameter calculation, BLQ values were set to zero

Table 4: Summary of Statistical Analysis of Uncorrected Derived Plasma Nicotine $C_{max,single}$, $C_{max,multiple}$ and AUC_{0-240} (PK Set)

Parameter	Number in Comparison	Geometric LSMeans (95% CI)		Geometric LSMean Ratio (%) (95% CI)	p-Value for Comparison	Within-Subject CV%
		Product A (N=20)	Product B (N=20)	Product B / Product A		
$C_{max,single}$ (ng/mL)	19	8.36 (6.29 - 11.10)	12.28 (9.24 - 16.32)	146.97 (120.00 - 180.01)	0.0009	30.2
$C_{max,multiple}$ (ng/mL)	20	7.69 (5.67 - 10.44)	11.65 (8.59 - 15.81)	151.50 (116.21 - 197.50)	0.0041	41.6
AUC_{0-240} (min*ng/mL)	19	640.77 (502.94 - 816.36)	783.96 (615.33 - 998.79)	122.35 (102.41 - 146.16)	0.0285	26.4

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).
Results obtained using an ANOVA with fixed effects for sequence, study day and product and a random effect of subject nested within sequence.

Table 5: Summary of Theoretical Nicotine Consumption (PP Set)

		Nicotine Consumption (mg)					
Product	Regimen	n	Mean	SD	Minimum	Median	Maximum
Product A	Single Use	20	1.1097	0.65256	0.178	0.8403	2.937
	Multiple Use	20	7.3158	5.13898	1.170	5.7320	17.825
Product B	Single Use	20	1.3275	0.66364	0.491	1.1521	3.097
	Multiple Use	20	8.7948	4.63552	2.792	8.0432	19.254

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).

Product A Theoretical amount consumed = (pre-use IP weight [mg] - post-use IP weight [mg]) x 0.0159.

Product B Theoretical amount consumed = (pre-use IP weight [mg] - post-use IP weight [mg]) x 0.0153.

Table 6: Summary of Intent to Use Product Again VAS Scores (Safety Set)

Product	Time-point	n	Mean	SD	Min	Median	Max
Product A	10 minutes	20	67.05	24.958	0.0	69.00	100.0
	10 hours	20	66.83	21.685	10.0	68.50	95.0
Product B	10 minutes	20	74.38	21.585	20.0	76.50	100.0
	10 hours	20	75.25	18.094	22.0	76.00	100.0

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).

Response measured on a 100mm VAS from 0-mm = “definitely would not” middle 50mm =”I don’t know” to 100-mm = “definitely would”.

Table 7: Summary of mPES Scores (Safety Set)

Subscale	Product	Time Point	n	Mean	SD	Min	Median	Max
Satisfaction	Product A	10 min	20	4.29	1.398	1.0	4.50	6.3
		10 h	20	4.13	1.262	2.0	3.70	6.0
	Product B	10 min	20	4.98	1.349	1.7	5.30	6.7
		10 h	20	4.71	1.067	2.0	5.00	6.3
Psychological Reward	Product A	10 min	20	4.25	1.441	1.4	4.60	6.0
		10 h	20	3.65	1.355	1.0	3.80	5.8
	Product B	10 min	20	3.87	1.265	1.8	3.70	6.0
		10 h	20	3.79	1.140	1.6	3.90	5.8
Enjoyment of Respiratory Tract Sensation	Product A	10 min	20	4.00	1.556	1.0	4.00	7.0
		10 h	20	4.05	1.395	2.0	4.00	7.0
	Product B	10 min	20	4.65	1.631	1.0	5.00	7.0
		10 h	20	4.50	1.192	1.0	4.50	6.0
Craving Reductions	Product A	10 min	20	4.90	1.586	1.0	5.00	7.0
		10 h	20	4.90	1.447	2.0	5.00	7.0
	Product B	10 min	20	5.45	1.234	3.0	6.00	7.0
		10 h	20	4.95	1.395	2.0	5.00	7.0
Aversion	Product A	10 min	20	2.38	1.512	1.0	1.75	5.5
		10 h	20	1.98	1.543	1.0	1.25	6.5
	Product B	10 min	20	2.35	1.479	1.0	2.00	6.0
		10 ho	20	2.13	1.327	1.0	1.50	4.5

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).

Scores were determined as "1-not at all, 2-very little, 3-a little, 4-moderately, 5-a lot, 6-quite a lot, 7-extremely" for each question.

Satisfaction subscale score derived as the mean of questions 1,2 and 12.

Psychological Reward subscale score derived as the mean of questions 4,5,6,7 and 8.

Enjoyment of Respiratory Tract Sensation subscale score is equivalent to the question 3 result.

Craving Reductions subscale score is equivalent to the question 11 result.

Aversion subscale score derived as the mean of questions 9 and 10.

Adverse Events

Throughout the study, four participants reported a total of five mild adverse events. One (1) AE was reported by 1 participant prior to product use and 4 AEs were reported by 3 participants after use of Product A or Product B (PEAEs).

Table 8: Overall Summary of PEAEs by Severity and Relationship (Safety Set)

	Product A (N=20)	Product B (N=20)	Overall (N=20)
Number of AEs after use of Product A or Product B (PEAEs)	3	1	4
Number (%) of participants reporting at least one:			
PEAE	2 (10.0)	1 (5.0)	3 (15.0)
Serious PEAE	0 (0.0)	0 (0.0)	0 (0.0)
PEAE Leading to Withdrawal of IP	0 (0.0)	0 (0.0)	0 (0.0)
PEAE Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Number (%) of participants with PEAE by severity:			
Mild	2 (10.0)	1 (5.0)	3 (15.0)
Moderate	0 (0.0)	0 (0.0)	0 (0.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)
Number (%) of participants with PEAE by relationship to IP:			
Reasonable possibility	1 (5.0)	0 (0.0)	1 (5.0)
No reasonable possibility	1 (5.0)	1 (5.0)	2 (10.0)

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).

A participant with multiple adverse events is counted only once at the maximum level of severity or the highest association to IP.

Percentages were calculated from the number of participants in the Safety Set within a product.

Table 9: PEAEs in each Product Use Group by System Organ Class and Preferred Term (Safety Set)

System Organ Class Preferred Term	Product A (N=20)	Product B (N=20)	Overall (N=20)
Nervous system disorders	2 / 2 (10.0)	0	2 / 2 (10.0)
Headache	2 / 2 (10.0)	0	2 / 2 (10.0)

System Organ Class Preferred Term	Product A (N=20)	Product B (N=20)	Overall (N=20)
Infections and infestations	0	1 / 1 (5.0)	1 / 1 (5.0)
Gastroenteritis	0	1 / 1 (5.0)	1 / 1 (5.0)
Respiratory, thoracic and mediastinal disorders	1 / 1 (5.0)	0	1 / 1 (5.0)
Hiccups	1 / 1 (5.0)	0	1 / 1 (5.0)

Product A: Logic Compact Tobacco Flavour (18 mg/mL nicotine).
Product B: Logic Compact, Intense Amber Tobacco Flavour (18 mg/mL nicotine, containing nicotine salts).

A participant is counted only once per System Organ Class and Preferred term.

Percentages were calculated from the number of participants in the Safety Set within a product.

MedDRA version 25.0.